Strong Start to Fiscal 2025

F. Hoffmann-La Roche AG announced a promising start to the fiscal year 2025, with first-quarter sales soaring to 15.4 billion Swiss francs. This marks a significant 7% increase in Swiss francs and a 6% rise at constant exchange rates (CER) compared to the previous year.

Pharmaceuticals Lead the Growth

The pharmaceuticals division stood out with an 8% growth at CER, achieving sales of 11.95 billion Swiss francs. Meanwhile, the diagnostics division maintained stability with sales of 3.49 billion Swiss francs, mirroring last year's figures.

CEO's Vision for Expansion

"We are off to a strong start this year, with Group sales climbing by 6% at constant exchange rates, and we've hit several key milestones," stated CEO Thomas Schinecker. He highlighted Roche's strategic investment of USD 50 billion to bolster its US presence, aiming to enhance patient access to innovative medicines and diagnostics through its extensive network of over 25,000 employees, 15 R&D, and 13 manufacturing sites.